Association of Uba6-Specific-E2 (USE1) With Lung Tumorigenesis

Kim, Seong‐Jin; Lee, Tae Hyeong; Nam, Sang Hee; Kim, Ji Eun; Oh, Sangho; Cho, Yeon Sook; Lee, Myeong Sup; Choi, Sehoon; Lee, Peter Chang-Whan

doi:10.1093/jnci/djw224

Cited by 20 publications

(13 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, FAT10 has demonstrated protumorigenic functions in hepatic and gastrointestinal malignancies (Lee et al, 2003;Yuan et al, 2014). Similarly, the UBA6-specific E2 enzyme UBA6-specific E2 conjugating enzyme 1 (USE1) is overexpressed in a subset of patients with lung cancer and promotes tumor growth, migration, and invasiveness (Kim et al, 2017). In contrast, UBA6 is inversely related to invasiveness in a subset of breast cancer in which it suppresses mammary carcinogenesis of breast cancer cells by inhibiting epithelial-mesenchymal transition (Liu et al, 2017b).…”

Section: Ubiquitin-like Modifier-activating Enzymementioning

confidence: 99%

E1 Enzymes as Therapeutic Targets in Cancer

Barghout¹,

Schimmer²

2020

Pharmacol Rev

View full text Add to dashboard Cite

show abstract

Section: Ubiquitin-like Modifier-activating Enzymementioning

confidence: 99%

E1 Enzymes as Therapeutic Targets in Cancer

Barghout¹,

Schimmer²

2020

Pharmacol Rev

View full text Add to dashboard Cite

show abstract

“…Kim et al found that 92.5% of tumor-normal-paired samples derived from 106 cancer patients showed a significantly upregulated USE1 expression, while the mRNA level of USE1 remained unchanged [112]. The unchanged mRNA level suggests an increased translation or decreased degradation of the USE1 protein in cancer tissues [113].…”

Section: Use1mentioning

confidence: 99%

UBA6 and Its Bispecific Pathways for Ubiquitin and FAT10

Wang¹,

Zhao²

2019

IJMS

View full text Add to dashboard Cite

Questions have been raised since the discovery of UBA6 and its significant coexistence with UBE1 in the ubiquitin–proteasome system (UPS). The facts that UBA6 has the dedicated E2 enzyme USE1 and the E1–E2 cascade can activate and transfer both ubiquitin and ubiquitin-like protein FAT10 have attracted a great deal of attention to the regulational mechanisms of the UBA6–USE1 cascade and to how FAT10 and ubiquitin differentiate with each other. This review recapitulates the latest advances in UBA6 and its bispecific UBA6–USE1 pathways for both ubiquitin and FAT10. The intricate networks of UBA6 and its interplays with ubiquitin and FAT10 are briefly reviewed, as are their individual and collective functions in diverse physiological conditions.

show abstract

“…A relevant study investigated UBA6-specific E2 conjugating enzyme 1 (USE1). The results showed that mutations in USE1 resulted in lung tumorigenesis by prolonging the half-life of the protein ( 52 ). We believe that USE1-associated UBA6 might be a participator in the prognosis of LUAD patients.…”

Section: Discussionmentioning

confidence: 99%

Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines

et al. 2021

View full text Add to dashboard Cite

mRNA vaccines against cancer have advantages in safety, improved therapeutic efficacy, and large-scale production. Therefore, our purpose is to identify immune biomarkers and to analyze immune status for developing mRNA vaccines and selecting appropriate patients for vaccination. We downloaded clinical information and RNA-seq data of 494 LUAD patients from TCGA. LUAD mutational information was hierarchically clustered by NMF package (Version 0.23.0). DeconstructSigs package (Version 1.8.0) and NMF consistency clustering were used to identify mutation signatures. Maftools package (Version 2.6.05) was used to select LUAD-related immune biomarkers. TIMER was used to discuss the correlation between genetic mutations and cellular components. Unsupervised clustering Pam method was used to identify LUAD immune subtypes. Log-rank test and univariate/multivariate cox regression were used to predict the prognosis of immune subtypes. Dimensionality reduction analysis was dedicated to the description of LUAD immune landscape. LUAD patients are classified into four signatures: T >C, APOBEC mutation, age, and tobacco. Then, GPRIN1, MYRF, PLXNB2, SLC9A4, TRIM29, UBA6, and XDH are potential LUAD-related immune biomarker candidates to activate the immune response. Next, we clustered five LUAD-related immune subtypes (IS1–IS5) by prognostic prediction. IS3 showed prolonged survival. The reliability of our five immune subtypes was validated by Thorsson’s results. IS2 and IS4 patients had high tumor mutation burden and large number of somatic mutations. Besides, we identified that immune subtypes of cold immunity (patients with IS2 and IS4) are ideal mRNA vaccination recipients. Finally, LUAD immune landscape revealed immune cells and prognostic conditions, which provides important information to select patients for vaccination. GPRIN1, MYRF, PLXNB2, SLC9A4, TRIM29, UBA6, and XDH are potential LUAD-related immune biomarker candidates to activate the immune response. Patients with IS2 and IS4 might potentially be immunization-sensitive patients for vaccination.

show abstract

Association of Uba6-Specific-E2 (USE1) With Lung Tumorigenesis

Cited by 20 publications

References 33 publications

E1 Enzymes as Therapeutic Targets in Cancer

E1 Enzymes as Therapeutic Targets in Cancer

UBA6 and Its Bispecific Pathways for Ubiquitin and FAT10

Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines

Contact Info

Product

Resources

About